Association of FMO3 variants and trimethylamine N-oxide concentration, disease progression, and mortality in CKD patients

Keyphrases

• Disease Progression 100%
• Disease-specific Mortality 100%
• Trimethylamine N-oxide 100%
• Chronic Kidney Disease Patients 100%
• Flavin-dependent Monooxygenase 100%
• Amino Acids 60%
• Genetic Variation 20%
• Prospective Cohort Study 20%
• Cardiovascular Disease 20%
• Kidney Disease Progression 20%
• Adverse Outcomes 20%
• Chronic Kidney Disease 20%
• Polymorphism 20%
• All-cause Mortality 20%
• High Risk 20%
• Metabolism 20%
• Clinical Outcomes 20%
• Mortality Risk 20%
• Disease Development 20%
• Trimethylamine 20%
• Variant Allele 20%
• Pharmacotherapy 20%
• Minor Allele 20%
• Functional Impact 20%
• Fast Rates 20%
• Allelic Variants 20%
• Dietary Modification 20%
• EGFR Decline 20%
• Homozygous Variant 20%
• Allele Variant 20%
• Heterozygous Variant 20%
• Reference Allele 20%
• Uremic Solutes 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Kidney Failure 100%
• Disease Exacerbation 100%
• Trimethylamine 100%
• Dimethylaniline Monooxygenase 100%
• Amino Acid 50%
• Adverse Outcome 16%
• Pharmacotherapy 16%
• All Cause Mortality 16%
• Prospective Cohort Study 16%
• Disease Course 16%
• Cardiovascular Disease 16%

Biochemistry, Genetics and Molecular Biology

• Isoform 100%
• Trimethylamine N-Oxide 100%
• Flavin-Containing Monooxygenase 100%
• Allele 60%
• Amino Acids 60%
• Metabolic Pathway 20%
• All Cause Mortality 20%
• Genetic Divergence 20%
• Genetic Variation 20%
• Prospective Cohort Study 20%
• Drug Therapy 20%